ClinicalTrials.gg
Active, not recruitingNCT03168516FiO2-CUpdated Dec 27, 2023

Effects of Closed-loop Automatic Control of FiO2 in Extremely Preterm Infants

A Phase 3 interventional study of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) in Infant,Premature, sponsored by University Hospital Tuebingen. Active, not recruiting at 32 sites in 4 countries. Open to participants aged Up to 48 Hours. Per ClinicalTrials.gov, last updated 2023-12-27.

Sponsored by University Hospital Tuebingen · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,065
Allocation
Randomized
Ages
Up to 48 Hours
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Premature Birth by University Hospital Tuebingen — 1 open to participants now, 3 under way, 1 of them phase 3. Premature Birth · University Hospital Tuebingen.

Started
2018
with 1 other
Phase 3
2 of 12
none open now
Registered
6th of 12
by date

Among the 12 studies in Premature Birth by University Hospital Tuebingen, this one is one of 2 that started in 2018, is one of 2 in phase 3, and was the 6th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

1 of the 12 studies in Premature Birth by University Hospital Tuebingen is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: Up to 48 Hours · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Premature Birth by University Hospital Tuebingen, or all of them as a file.
02

Study summary

Extremely low gestational age neonates (ELGANs), i.e. those born at \<28 weeks, frequently experience intermittent hypoxemic/hyperoxemic episodes. Observational data indicate that severe and prolonged hypoxemic episodes are associated with retinopathy of prematurity (ROP), impaired long-term development and death. Closed-loop automated control of the inspiratory fraction of oxygen (FiO2-C) reduces time outside the oxygen target range, decreases number and duration of hypo- and hyperoxemic episodes, and reduces caregivers' workload. The proposed observer-blinded randomized controlled trial was designed and will be powered to compare the effect of FiO2-C in addition to manual adjustments, in comparison with manual adjustments of FiO2 only, on death and severe complications of prematurity thought to be related to hypoxia/hyperoxia and neurodevelopmental impairment in ELGANs. The results of this trial may help to improve the quality of life of ELGANs and reduce the burden of significant morbidity as well as costs for health care and society

Read the detailed description

Approximately 0.5% of all neonates (i.e., about 25,000 infants per year in Europe) are extremely low gestational age neonates (ELGANs), i.e. have a gestational age (GA) of \<28 completed weeks at birth. ELGANs have higher incidences of mortality, retinopathy of prematurity (ROP), chronic lung disease and other risks of prematurity as well as severe neurodevelopmental impairment.

The vast majority of ELGANs require supplemental oxygen in addition to mechanical respiratory support (including CPAP). Irrespective of the SpO2 target, the vast majority of ELGANs suffers from recurrent intermittent hypoxemic and (as a consequence of inappropriate adjustments of FiO2) hyperoxemic episodes. Recurrent intermittent hypoxic episodes - i.e. wide fluctuations in oxygen levels - are associated with an increased risk of ROP and there are data that suggest that late deaths and neurodevelopmental impairment are also linked to them.

Continuous positive airway pressure (CPAP) has been shown to reduce extubation failure in preterm infants, which may in part be due to a reduced frequency and severity of apnea of prematurity and stabilized functional residual capacity during apnea. Keeping oxygen levels (i.e., SpO2) stable despite irregular breathing patterns in ELGANs, requires frequent adjustments of the FiO2 which is both challenging, time consuming, and often impossible due to limited personnel resources.

FiO2-Controllers have been developed by several manufacturers of infant ventilators. They reduce the burden of hyper-/hypoxemia in infants while being safe and accurate in very short-term studies. The effects of FiO2-C on clinically relevant outcome measures and the safety of long-term continuous application, however, have yet to be elucidated. Hence there is now a window of opportunity to assess this new technology for benefits and harms, before it is implemented into neonatal care without appropriate evaluation of its safety and efficacy.

03

Conditions studied

  • Infant,Premature

Browse trials for

Keywords

  • Oxygen
  • closed-loop automatic control
  • Oxygen saturation
  • preterm infants
04

Who can participate

Ages eligible
Up to 48 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infants with a gestational age (GA) at birth of 23+0/7 - 27+6/7 weeks

Exclusion criteria

Exclusion Criteria:

  • Decision for palliative care
  • congenital anomalies
  • postnatal age > 48h
  • missing parental consent
  • lack of device enabling closed-loop automatic control of FiO2
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,065 participants (actual)

Study arms

  • Experimental
    Experimental intervention

    closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)

    Device: closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)

  • No intervention
    Control intervention

    Standard care, i.e. manual adjustments of the FiO2 only

Interventions

  • Deviceclosed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)

    Application of FiO2-C (provided by standard infant ventilators) in addition to manual adjustments of the inspired oxygen fraction (FiO2) during mechanical ventilation and continuous positive airway pressure (CPAP) in ELGANs at least up to 32weeks PMA according to a standardized protocol

06

What researchers measure

Primary outcomes

  1. Primary outcome I: composite outcome of death, severe retinopathy of prematurity (ROP), chronic lung disease of prematurity (BPD), necrotizing enterocolitis (NEC)

    The primary outcome I is a composite of any of the following: * Death * Severe retinopathy of prematurity (severe ROP, as defined in 7.3.1) * Chronic lung disease of prematurity (BPD, according to the physiological definition, which is described in detail in the study protocol) * Necrotizing enterocolitis (NEC, as defined in the study protocol) until discharge from hospital The primary endpoint I will be analysed between the two intervention groups using a stratified chi2-test and Cochrane Mantel-Haenszel statistics will be presented (risk ratios and 95%-confidence intervals). The factors considered for randomization (center, sex and gestational age at birth (\<26 weeks and ≥26 weeks) will also be used for analysis.

    Time frame: until/at post-menstrual age (PMA) 36 weeks (death, BPD and NEC) and at latest at PMA 44 weeks for severity of ROP

  2. Primary outcome II: composite of death or neurodevelopmental impairment (NDI)

    The primary outcome II is a composite of any of the following: • death or neurodevelopmental impairment (defined as at least one of the following components: motor disability (GMFCS 2-5), language or cognitive delay (language composite score \< 85 or cognitive composite score \< 85 on Bayley Scales of Infant Development, 3rd edition) or severe visual or hearing impairment (need for a hearing aid or cochlear implant)). In case of missing Bayley III test results, Bayley II results, other developmental test results or PARCA-R parent questionnaire results may substitute for the Bayley III test results in a hierarchical manner described in the study protocol. The primary outcome II will be analysed between the two intervention groups using chi2-test and Cochrane Mantel-Haenszel statistics will be presented (risk ratios and 95%-confidence intervals). The factors considered for randomization (center, sex and gestational age at birth (\<26 weeks and ≥26 weeks) will also be used for analysis.

    Time frame: at 24 months of age corrected for prematurity

Secondary outcomes

  1. Death

    Death rates will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.

    Time frame: 24 months of age corrected for prematurity

  2. ROP Severity Score

    The most severe grade of ROP according to 25 categories currently developed by the working group of the international neonatal consortium (may have to be adapted as the consensus process proceeds), documented in either eye (for at least 2 consecutive examinations) will be analysed using Wilcoxon-Mann-Whitney test.

    Time frame: at latest at PMA 44 weeks

  3. Severe ROP

    defined as: ROP stage 0, 1 or 2 (in Zone 2 or 3) = no/non-severe ROP versus 3, 4 or 5, or AP-ROP, or any ROP in Zone 1, or any treatment for ROP = severe ROP. Rates of severe ROP will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.

    Time frame: at latest at PMA 44 weeks

  4. bronchopulmonary Dysplasia (BPD)

    As part of routine care, the presence of BPD will be determined at 36 weeks postmenstrual age (PMA) according to the physiological definition of Walsh et al. \[Walsh, J Perinatol 2003\]. BPD rates will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.

    Time frame: until 36 weeks PMA

  5. Necrotizing enterocolitis (NEC)

    NEC (modified Bell stage ≥ IIA according to \[Bell, Ann Surg 1978\]) or intestinal perforation will be diagnosed at surgery, at autopsy, or by either the finding of pneumatosis intestinalis, hepatobiliary gas, or free intraperitoneal air on abdominal x-ray, or by demonstration of gas (bubbles) in the portal vein on abdominal ultrasound or abdominal x-ray. NEC rates will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.

    Time frame: until 36 weeks PMA

  6. Neurodevelopmental impairment (NDI)

    NDI is defined as at least one of the following components: motor disability (modified GMFCS 2-5), language or cognitive delay (language composite score \< 85 or cognitive composite score \< 85 on Bayley Scales of Infant Development, 3rd edition) or severe visual or hearing impairment (need for a hearing aid or cochlear implant). In case of missing Bayley III test results, Bayley II results, other developmental test results or PARCA-R parent questionnaire results may substitute for the Bayley III test results in a hierarchical manner described in the study protocol. NDI rates will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.

    Time frame: at 24 months of age corrected for prematurity

  7. Bayley III. Language composite score - dichotomized

    The results of the language composite score of the Bayley Scales of Infant Development, 3rd edition, will be dichotomized by \<85 (abnormal) versus \>=85 (normal) and compared between the two treatment groups by Cochrane-Mantel-Haenszel- X²-Test.

    Time frame: at 24 months of age corrected for prematurity

  8. Bayley III: Language composite score - numerical

    The raw numerical data of the language-composite-score will be analysed using Wilcoxon-Mann-Whitney test. The use of this test accounts for the fact that data will be cut due to lack sensitivity below 50 points.

    Time frame: at 24 months corrected age

  9. Bayley III: Cognitive composite score - dichotomized

    The results of the cognitive composite score of the Bayley Scales of Infant Development, 3rd edition, will be dichotomized by \<85 (abnormal) versus \>=85 (normal) and compared between the two treatment groups by Cochrane-Mantel-Haenszel- X²-Test.

    Time frame: at 24 months of age corrected for prematurity

  10. Bayley III: Cognitive composite score - numerical

    The numerical data of the cognitive-composite-score will be analysed using Wilcoxon-Mann-Whitney test. The use of this test accounts for the fact that data will be cut due to lack sensitivity below 50 points.

    Time frame: at 24 months of age corrected for prematurity

  11. Cerebral palsy

    Cerebral palsy will be diagnosed if the child has a non-progressive motor impairment characterized by abnormal muscle tone and impaired range or control of movements, according to the criteria defined by the European network 'Surveillance of CP in Europe'. Rates of cerebral palsy will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.

    Time frame: at 24 months of age corrected for prematurity

  12. Motor disability

    Motor disability is defined as a modified GMFCS 2-5 versus a modified GMFCS 0-1, which is regarded as being normal. Rates of motor disability will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.

    Time frame: at 24 months of age corrected for prematurity

  13. Score data of modified Gross Motor Function Classification Scale (GMFCS)

    GMFCS-Score for quantification of the effects of cerebral palsy and other motor impairments (adapted from Palisano et al. \[Palisano Med Child Neurol 1997\]) using the FiO2-C-GMFCS-score sheet (separate document not part of this protocol) will be analysed. GMFCS-score consists of six categories. Analysis will be done by using Wilcoxon-Mann-Whitney test.

    Time frame: at 24 months of age corrected for prematurity

  14. Bayley III: Motor composite score - numerical

    The numerical data of the motor-composite-score will be analysed using Wilcoxon-Mann-Whitney test. The use of this test accounts for the fact that data will be cut due to lack of sensitivity below 50 points.

    Time frame: at 24 months of age corrected for prematurity

  15. Severe visual impairment

    Severe visual impairment is defined as an ophthalmological assesment indicating "severe visual impairment", e.g. the best corrected vision in the better eye yields a visual acuity less than 6/60 m (20/200 ft). Rates will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.

    Time frame: at 24 months of age corrected for prematurity

  16. Severe hearing impairment

    Severe hearing impairment is defined as need for a hearing aid or cochlear implant. Rates will be compared between the two treatment groups and analyzed by Cochrane-Mantel-Haenszel- X²-Test.

    Time frame: at 24 months of age corrected for prematurity

07

Study locations

32 sites
08

References and documents

Publications

  • Maiwald CA, Niemarkt HJ, Poets CF, Urschitz MS, Konig J, Hummler H, Bassler D, Engel C, Franz AR; FiO2-C Study Group. Effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcome of extremely preterm infants - study protocol of a randomized controlled parallel group multicenter trial for safety and efficacy. BMC Pediatr. 2019 Oct 21;19(1):363. doi: 10.1186/s12887-019-1735-9. PubMed 31630690 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2018 (actual). Primary completion is estimated for Dec 2026, 101 months after the start.

Of 35 non-industry phase 3 interventional studies under Premature Birth, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 89. This study's planned 101 months is above that.

Counting every sponsor, half of 40 studies reached it within 51 months; a quarter within 28 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2017
First posted
May 30, 2017
StartActual
Jul 27, 2018
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03168516
Responsible party
Sponsor
First posted
May 30, 2017
Start date
Jul 27, 2018
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 27, 2023

Study contacts

Axel Franz, Prof. Dr.
study director · University Children's Hospital Tuebingen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion